How Does BICO Company Work?

How is BICO reshaping bio-convergence?

BICO Group AB has built a stabilized revenue base above 2.4 billion SEK (2025 projections) by merging biology, robotics and diagnostics. With over 35,000 instruments installed, it enables tissue engineering and high-throughput drug screening for pharma and academia.

BICO sits at the nexus of personalized medicine and lab automation, turning complex biological workflows into scalable instrument and consumable sales. Its platform approach reduces reliance on animal testing and supports long-term recurring revenue.

How does BICO work? It sells integrated hardware, software and consumables to automate bioprinting, cell handling and diagnostics, monetizing instruments, consumables, service and data through partnerships and licensing. See product analysis: BICO Porter's Five Forces Analysis

BICO operates across Bioprinting, Biosciences and Bioautomation to shorten drug discovery timelines and reduce animal testing, combining precision instruments, consumables and software into an integrated platform.

Primary business areas

BICO company operations are organized into three segments: Bioprinting (hardware and bioinks), Biosciences (cell line and assay services) and Bioautomation (liquid handlers and workflow automation).

Value proposition

How BICO works to deliver value: accelerate drug discovery, lower reliance on animal models and enable reproducible human-relevant biology through an end-to-end technology platform.

Manufacturing & R&D

High-precision manufacturing sites in Sweden, Germany and the United States produce instruments; R&D accounts for approximately 11 percent of annual expenditures to sustain platform leadership.

Go-to-market

Direct sales focus on North America and Europe while a distributor network covers the Asia-Pacific region, ensuring broad access to BICO technology platform and services.

The operational model integrates proprietary hardware like the BIO X6 bioprinter and the C.WASH liquid handler with software, bioinks and consumables to automate labor‑intensive workflows and create recurring consumable revenue.

Operational strengths and moat

BICO’s cross-disciplinary architecture—from instrument design to high-volume consumables—builds a competitive moat that few rivals can replicate.

• Integrated ecosystem: hardware, software, biological materials and services.
• Supply chain optimized for high-mix low-volume instruments and high-volume consumables.
• Commercial mix: direct sales + distributor network enabling global reach.
• R&D intensity: sustained 11 percent investment supports product cadence and platform upgrades.

For a strategic perspective on market positioning and growth initiatives, see Growth Strategy of BICO

Revenue generation is diversified across capital equipment sales, high-margin consumables, and recurring service contracts; in 2025 instrument sales remain the largest contributor while consumables and services drive margin expansion and recurring cash flow.

Capital equipment sales

In 2025 instrument sales account for 62% of total revenue, driven by bioprinters and analytical platforms sold to labs and manufacturers.

Consumables (razor-and-blade)

Consumables—bioinks, specialized plates, pipette tips—now represent 26% of revenue and deliver materially higher gross margins than hardware.

Software and licenses

Software licenses contribute part of the recurring revenue mix, bundled with instruments for workflow automation and compliance tracking.

Service and maintenance contracts

Long-term service agreements and support represent roughly 12% of revenue, offering predictable, recurring cash flow and customer retention.

Tiered pricing strategy

Pricing tiers address both academic labs and large pharma, enabling wider adoption while protecting margins through volume and premium support offerings.

Cross-selling and portfolio integration

Cross-selling between subsidiaries—such as offering Cytena cell-line tools to CELLINK bioprinting customers—increases customer lifetime value and accelerates consumable uptake.

Geographic and financial mix underpin monetization: North America accounts for 45% of sales, Europe 35%, and APAC/emerging markets 20%, supporting the goal of a sustainable gross margin above 70% in the biosciences portfolio; see related context in Brief History of BICO.

Monetization levers and KPIs

Key levers include shifting mix to consumables, expanding service attach rates, and growing software subscriptions to stabilize recurring revenue.

• Instrument sales: 62% of revenue in 2025
• Consumables: 26% of revenue, higher gross margin
• Software & services: 12% of revenue, recurring cash flow
• Geographic split: NA 45%, EU 35%, APAC/emerging 20%

BICO’s key milestones and strategic moves from 2024–2025 centered on restructuring to balance decentralized business units with centralized financial controls, divesting non-core assets, and prioritizing organic integration into high-growth areas such as single-cell analysis and automated liquid handling.

Organizational Restructuring

The 2024–2025 restructuring decentralized operations for agility while centralizing finance to drive profitability, targeting an improved EBITDA margin of 13 percent by end-2025.

Portfolio Rationalization

BICO divested non-core assets post-pandemic and shifted from aggressive M&A to organic integration, reallocating capital to core technologies like bioprinting and automation.

Focus Areas

Strategic emphasis on single-cell analysis, automated liquid handling and complete workflow solutions strengthened recurring revenue opportunities and customer retention.

Financial Turnaround

Improved operational discipline and targeted investments supported recovery from negative margins to positive EBITDA trajectory, with cost structure optimization and selective R&D spend.

Key competitive advantages derive from a broad patent portfolio, an ecosystem effect around the bioprinting platform, academic market dominance, and an end-to-end technology platform that lowers churn and raises switching costs for customers.

Competitive Edge and Market Position

BICO’s technology platform and integrated workflow—from cell isolation to tissue printing and analysis—create a differentiated value proposition that competitors offering standalone components struggle to match.

• Extensive patent protection increases barriers to entry and secures IP around proprietary bioinks and hardware.
• High switching costs for laboratories due to specialized bioinks and workflow integrations bolster customer lifetime value.
• Academic adoption fuels future industrial and commercial demand by training the next generation on BICO equipment.
• Consolidated financial controls enabled clearer ROI tracking and supported the pivot to organic growth.

For a detailed breakdown of revenue mix and business model mechanics, see Revenue Streams & Business Model of BICO.

BICO holds a leading position in global bioprinting with an estimated market share above 30% as of early 2026, while navigating R&D budget shifts and supply-chain pressures; its move to positive free cash flow in 2025 has materially de-risked the balance sheet and supports clinical and AI-led expansion.

Industry Position

BICO company operations center on bioprinting, bioautomation and consumables, enabling the company to capture >30 percent of the global bioprinting market by early 2026. The BICO technology platform spans instruments, software and consumables, supporting customers from academia to pharma.

Market Reach

Revenue mix in 2025 showed improving recurring revenues from consumables and software alongside instrument sales; clinical and drug-discovery clients now account for an increasing share of contracts as BICO business model shifts toward regulated applications.

Key Risks

Primary risks include biotech R&D budget volatility, competition from niche high-throughput screening vendors, interest-rate swings affecting capital costs, and geopolitical supply-chain risks tied to China. Management highlights supply-chain resilience and margin recovery as priorities.

Financial Trajectory

After returning to positive free cash flow in 2025 and targeting an EBITDA margin of 12–15% for 2025, the firm is focused on sustainable profitability and deeper penetration into the multi-billion dollar drug discovery market.

Strategic focus combines clinical validation, AI integration into bioautomation, and operational efficiency to convert research customers into recurring clinical and discovery revenue streams.

Future Outlook

Leadership outlines a roadmap from research-only use cases toward regulated diagnostics and therapeutic tissue production, positioning BICO as an operating system for modern biology.

• Clinical expansion: moving into regulated markets increases addressable market and long-term service revenue.
• AI and automation: integrating AI into the BICO technology platform enhances throughput and predictive maintenance.
• Margin targets: management aims for 12–15% EBITDA in 2025 and continued efficiency gains thereafter.
• Market penetration: priority is expanding share in drug discovery, leveraging consumables and software to build recurring revenue.

For further detail on strategy and go-to-market, see Marketing Strategy of BICO.